Cancer Clinical Trial
Official title:
Catheter Resistance Monitoring to Predict Catheter-Associated Adverse Events in Children and Adolescents: A Feasibility Study
Catheter occlusion and dysfunction are common complications of central venous access device
(CVAD) use in children with cancer and hematologic disorders. These events can lead to
interruption of therapy and may require device removal and replacement. Attempts to clear
occlusion can cause device fracture.
There is a clear link between catheter occlusion and other serious complications including
bloodstream infection and intravascular thrombosis.
There is evidence that catheter occlusion or dysfunction may be preceded by subclinical
catheter narrowing, which could be detected by accurate measurement of catheter resistance.
This study aims to observe and describe the feasibility and results of catheter resistance
monitoring (CRM) over time with the aim of prospectively identifying patients at high risk
of catheter occlusion.
If CRM is feasible and proves to be sensitive and specific, it could provide an opportunity
for preemptive therapy to prevent occlusion, which might also prevent bloodstream infection
or thrombosis.
Weekly measurement of catheter resistance will be determined using the Alaris® Syringe
Module (Carefusion Inc., San Diego, USA), a commercially available, FDA-approved intravenous
(IV) pump which is able to deliver accurate flow-rates and obtain accurate pressure
measurements. The inline pressure will be measured at multiple flow-rates and resistance
will be estimated from the gradient of the pressure-flow curve.
Primary Objective
- To describe the feasibility of weekly CRM in children and adolescents treated at St.
Jude.
Secondary Objectives
- To describe patient and caregiver adherence with weekly CRM in children and adolescents
treated at St. Jude.
- To explore the correlation between results of CRM and catheter occlusion or
dysfunction.
;
Observational Model: Cohort, Time Perspective: Prospective
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05346796 -
Survivorship Plan HEalth REcord (SPHERE) Implementation Trial
|
N/A | |
| Recruiting |
NCT05094804 -
A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents
|
Phase 1/Phase 2 | |
| Completed |
NCT04867850 -
Effect of Behavioral Nudges on Serious Illness Conversation Documentation
|
N/A | |
| Enrolling by invitation |
NCT04086251 -
Remote Electronic Patient Monitoring in Oncology Patients
|
N/A | |
| Completed |
NCT01285037 -
A Study of LY2801653 in Advanced Cancer
|
Phase 1 | |
| Completed |
NCT00680992 -
Study of Denosumab in Subjects With Giant Cell Tumor of Bone
|
Phase 2 | |
| Completed |
NCT00062842 -
Study of Irinotecan on a Weekly Schedule in Children
|
Phase 1 | |
| Active, not recruiting |
NCT04548063 -
Consent Forms in Cancer Research: Examining the Effect of Length on Readability
|
N/A | |
| Completed |
NCT04337203 -
Shared Healthcare Actions and Reflections Electronic Systems in Survivorship
|
N/A | |
| Recruiting |
NCT04349293 -
Ex-vivo Evaluation of the Reactivity of the Immune Infiltrate of Cancers to Treatments With Monoclonal Antibodies Targeting the Immunomodulatory Pathways
|
N/A | |
| Terminated |
NCT02866851 -
Feasibility Study of Monitoring by Web-application on Cytopenia Related to Chemotherapy
|
N/A | |
| Active, not recruiting |
NCT05304988 -
Development and Validation of the EFT for Adolescents With Cancer
|
||
| Completed |
NCT00340522 -
Childhood Cancer and Plexiform Neurofibroma Tissue Microarray for Molecular Target Screening and Clinical Drug Development
|
||
| Recruiting |
NCT04843891 -
Evaluation of PET Probe [64]Cu-Macrin in Cardiovascular Disease, Cancer and Sarcoidosis.
|
Phase 1 | |
| Active, not recruiting |
NCT03844048 -
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
|
Phase 3 | |
| Completed |
NCT03167372 -
Pilot Comparison of N-of-1 Trials of Light Therapy
|
N/A | |
| Completed |
NCT03109041 -
Initial Feasibility Study to Treat Resectable Pancreatic Cancer With a Planar LDR Source
|
Phase 1 | |
| Terminated |
NCT01441115 -
ECI301 and Radiation for Advanced or Metastatic Cancer
|
Phase 1 | |
| Recruiting |
NCT06206785 -
Resting Energy Expenditure in Palliative Cancer Patients
|
||
| Recruiting |
NCT05318196 -
Molecular Prediction of Development, Progression or Complications of Kidney, Immune or Transplantation-related Diseases
|